HUTCHMED: ORPATHYS And TAGRISSO Get Breakthrough Therapy Designation In China For NSCLC
Limited (HCM) announced that the Center for Drug Evaluation of Chinas National Medical Products Administration or ...
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...
Hosted on MSN1d
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...
Medscape10d
EGF Receptor Tyrosine Kinase Inhibitors in the Treatment of Brain Metastases From Non-small-cell Lung Cancer
EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...
Pharmabiz2d
US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC
US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...
healthandpharma2d
FDA Grants Breakthrough Status to Datopotamab Deruxtecan for Advanced EGFR-Mutated Lung Cancer
The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.
The Pharma Letter2d
First ‘Breakthrough’ designation for datopotamab deruxtecan
Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy designation (BTD) by the US Food and Drug ...
Rare NRG1 Fusion Therapeutics Market Size in the 7MM was ~USD 37 million in 2023, estimated DelveInsight
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Rare NRG1 Fusion Therapeutics ...
LJMU12d
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
colorectal (colon) cancer; epidermal growth factor receptor (EGFR); RAS; liquid biopsy; rechallenge; cetuximab; RAS; ...
Targeted Oncology7d
FDA Grants Breakthrough Status to Sacituzumab Tirumotecan in EGFR+ NSCLC
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.